Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Prazosin measurement |
Component |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Prazosin adverse reaction |
Causative agent (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Allergy to prazosin |
Causative agent (attribute) |
False |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Furazosin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Prazosin hydrochloride (substance) |
Is a |
False |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing prazosin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Allergy to prazosin |
Causative agent (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely prazosin (as prazosin hydrochloride) 500 microgram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely prazosin (as prazosin hydrochloride) 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Prazosin (as prazosin hydrochloride) 2 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Prazosin hydrochloride 5mg tablet (substance) |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Prazosin hydrochloride (substance) |
Is modification of (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Prazosin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing only prazosin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing only prazosin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely polythiazide 500 microgram and prazosin (as prazosin hydrochloride) 5 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Polythiazide 500 microgram and prazosin (as prazosin hydrochloride) 1 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely polythiazide 500 microgram and prazosin (as prazosin hydrochloride) 2 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing polythiazide and prazosin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Polythiazide and prazosin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Polythiazide- and prazosin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Polythiazide and prazosin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Prazosin (as prazosin hydrochloride) 5 mg prolonged-release oral tablet |
Has basis of strength substance (attribute) |
True |
Prazosin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |